BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 15907526)

  • 1. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.
    Matthai WH; Hursting MJ; Lewis BE; Kelton JG
    Thromb Res; 2005; 116(2):121-6. PubMed ID: 15907526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
    Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
    Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
    Bartholomew JR; Pietrangeli CE; Hursting MJ
    Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Leya F; Hursting MJ; Kelton JG;
    Arch Intern Med; 2003 Aug 11-25; 163(15):1849-56. PubMed ID: 12912723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients.
    Gray A; Wallis DE; Hursting MJ; Katz E; Lewis BE
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):353-61. PubMed ID: 17911186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
    Levine RL; Hursting MJ; McCollum D
    Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD.
    Dager WE; White RH
    Ann Pharmacother; 2003 Sep; 37(9):1232-6. PubMed ID: 12921505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
    Lewis BE; Wallis DE; Berkowitz SD; Matthai WH; Fareed J; Walenga JM; Bartholomew J; Sham R; Lerner RG; Zeigler ZR; Rustagi PK; Jang IK; Rifkin SD; Moran J; Hursting MJ; Kelton JG;
    Circulation; 2001 Apr; 103(14):1838-43. PubMed ID: 11294800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study.
    Young G; Boshkov LK; Sullivan JE; Raffini LJ; Cox DS; Boyle DA; Kallender H; Tarka EA; Soffer J; Hursting MJ
    Pediatr Blood Cancer; 2011 Jul; 56(7):1103-9. PubMed ID: 21488155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
    Guzzi LM; McCollum DA; Hursting MJ
    J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
    Hursting MJ; Verme-Gibboney CN
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):561-6. PubMed ID: 19057393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR).
    Bartholomew JR; Hursting MJ
    J Thromb Thrombolysis; 2005 Jun; 19(3):183-8. PubMed ID: 16082605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Argatroban dosing in patients with heparin-induced thrombocytopenia.
    Verme-Gibboney CN; Hursting MJ
    Ann Pharmacother; 2003; 37(7-8):970-5. PubMed ID: 12841802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the PREVENT-HIT study: a randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis.
    Frame JN; Rice L; Bartholomew JR; Whelton A
    Clin Ther; 2010 Apr; 32(4):626-36. PubMed ID: 20435232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.
    Boyce SW; Bandyk DF; Bartholomew JR; Frame JN; Rice L
    Am J Ther; 2011 Jan; 18(1):14-22. PubMed ID: 21079512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Argatroban anticoagulation for heparin induced thrombocytopenia in patients with ventricular assist devices.
    Pappalardo F; Scandroglio AM; Potapov E; Stepanenko A; Maj G; Krabatsch T; Zangrillo A; Koster A; Hetzer R
    Minerva Anestesiol; 2012 Mar; 78(3):330-5. PubMed ID: 22357371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE; Matthai WH; Cohen M; Moses JW; Hursting MJ; Leya F;
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):177-84. PubMed ID: 12357516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
    Kiser TH; Jung R; MacLaren R; Fish DN
    Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
    Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
    Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.
    Tang IY; Cox DS; Patel K; Reddy BV; Nahlik L; Trevino S; Murray PT
    Ann Pharmacother; 2005 Feb; 39(2):231-6. PubMed ID: 15632219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.